Navigation Links
Labopharm Reports Results for Third Quarter Fiscal 2007
Date:11/9/2007

for the first nine months of fiscal 2007 were $2.4 million compared to $1.8 million for the first nine months of fiscal 2006.

Selling, general and administrative costs for the first nine months of fiscal 2007 increased to $16.0 million from $11.1 million for the first nine months of fiscal 2006. The rationale for the increase is consistent with that for the third quarter and also includes an increase in non-cash stock-based compensation expense of $1.3 million.

Net loss for the first nine months of fiscal 2007 was $26.5 million, or $0.47 per share, compared to $16.7 million, or $0.33 per share for the first nine months of fiscal 2006.

Labopharm continues to expect global sales of its once-daily tramadol product to be variable from quarter to quarter as a result of pipeline fill and other supply chain and market dynamics associated with the early stages of product launches. Labopharm believes that the continued penetration of markets in which its product has already been launched, as well as additional product launches globally, will result in quarter over quarter growth in product sales.

Conference Call

Labopharm will host a conference call today (Friday, November 9, 2007 at 8:30 a.m. ET) to discuss its third quarter fiscal 2007 results. To access the conference call by telephone, dial (416) 644-3427 or 1-800-589-8577. Please connect approximately five minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Friday, November 16, 2007 at midnight. To access the archived conference call, dial (416) 640-1917 or 1-877-289-8525 and enter the reservation number 21251082 followed by the number sign. A live audio webcast of the conference call will be available at http://www.labopharm.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to jo
'/>"/>

SOURCE Labopharm Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
8. Haemacure Reports Third Quarter 2007 Results
9. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
10. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
11. MDS Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2
...cancer, constipation and other conditions may soon...f using injections.Scientists in India have develo...s to manage diseases that often require an injecti...nfections. The new gel can also prevent problems c...
...combined efforts to determine the potential health...looked at 20 risk factors.// Some of those include... and hygiene, indoor smoke, childhood sexual abuse...7 percent of premature deaths and 39 percent of to...
...al activity of adults with asthma. Knowing if asth...ing could help health professionals in designing f...the Centers for Disease Control and Prevention con...ctivity levels of adults with asthma. The study in...
..., frequent urination or abnormal periods, uterine ...rous // growths found in the uterus and can range ...e or larger. Now, there’s an improvement to uterin...at’s becoming the procedure of choice for many wom...
Other Medicine News:
(Date:9/4/2008)...o Enroll 750 Women at More Than 100 Sites in the U...atRx Pharmaceuticals, a,privately-held biopharmace...alization of compounds to treat endocrine, metabol...hat it has initiated a second,Phase 3 clinical tri...,s,estrogen-free oral therapy in development for t...
(Date:9/4/2008)...Remain on Schedule with Two Abstracts Accepted for... in November 2008, BRIDGEWATER, N.J., Sept. 4 /PR...cialty pharmaceutical company focused on the treat...y announced the appointment of,Peter L. Garrambone... Garrambone,s career includes more than 50 pharmac...
(Date:9/3/2008)... up results from chronically infected Hepatitis C,... obtained earlier in 2008, - Study is the first ... antiviral effect of therapeutic Hepatitis C...upport move into a second generation, vaccine for...hrough TLR activatio...
(Date:9/3/2008)...ny to Discuss Phase 3 Plans with FDA, PRINCETON, ...Inc.,announced today that it successfully complet...he company,s new, innovative low-dose, once-weekly... by its internal product,code AG-200-15. The Phase...,primary endpoint of ovulation suppression, cycle ...
Breaking Medicine Technology:QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 2QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 3Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Male kidneys for men only 3F 23584 1Male kidneys for men only 3F 23584 2U M study 3A Herceptin targets breast cancer stem cells 3963 1U M study 3A Herceptin targets breast cancer stem cells 3963 2Big brains arose twice in higher primates 3959 1Big brains arose twice in higher primates 3959 2ACS Forum to Showcase Innovative Healthcare Model for European Union 23578 1ACS Forum to Showcase Innovative Healthcare Model for European Union 23578 2ACS Forum to Showcase Innovative Healthcare Model for European Union 23578 3
...AILEA, Hawaii and SUNNYVALE, Calif., June 27, 2007...ay announced,preliminary results from two open-lab...g the potential use of Xcytrin(R),(motexafin gadol...date, in combination with Alimta(R) (pemetrexed) a...a second-line treatment,for patients with non-smal...
...N DIEGO--(BUSINESS WIRE)--Jun 27, 2007 - The Unive...ed the following study and,press release, "Scienti...t Tissue," June 15, 2007, Science Daily: "Research...cine have successfully,isolated and cultured human...sue, suggesting that they have found another impor...
Other Medicine Technology:Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 2Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 3Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 4Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 5Bio-Matrix Scientific's Dr. O'Neill Sees University of Pittsburgh's,Published Study on Culture Blood-Forming Stem Cells from Human Fat,Tissue as Supporting Near Term Benefits of Banking Adipose (Fat),Derived Stem Cells 2Bio-Matrix Scientific's Dr. O'Neill Sees University of Pittsburgh's,Published Study on Culture Blood-Forming Stem Cells from Human Fat,Tissue as Supporting Near Term Benefits of Banking Adipose (Fat),Derived Stem Cells 3
...ries Freezing Stages fit easily onto most microtom...arts and need only the AC supply and a trickle of ...ediately and can be maintained indefinitely. Stag...g temperatures can be set for different kinds of t...
ELISA kit for the quantitative determination of autoantibodies to glutamic acid decarboxylase (GAD65) in serum
ELISA kit for the quantitative determination of autoantibodies to IA-2 in serum
RIA kit for the quantitative determination of autoantibodies to insulin in serum
Medicine Products: